SANTA ANA, Calif., July 1, 2002 (PRIMEZONE) -- National Capital Securities, Inc. (formerly known as Donner Corp. International), a subsidiary of National Capital Companies, Inc. (Pink Sheets:NATC), announced today that it released its Speculative Buy Recommendation on HyperBaric Systems, Inc. (OTCBB:HYRB).
The report which can be found at www.donnercorp.com, highlighted the Company's potential to dominate an enormous global market that is demanding advancements in technology that allow for the extended storage and preservation of biomaterials.
National stated in the report that HyperBaric's technology represents a long-awaited solution to blood platelet spoilage which results in millions in lost revenue to hospitals and blood centers. HyperBaric has made a breakthrough in research and development in the field of living biological material storage and preservation. By enabling organs and blood platelets to be preserved for a longer time and higher quality level than ever before, HyperBaric's technology represents an important complement to other emerging life saving technologies.
HyperBaric's technology consists of a set of liquid solutions, a lightweight, portable device for cooling and processing, and the protocols for using the solutions and device. The Company is currently preparing to conduct human infusion tests, a major step in the regulatory path to FDA approval, and is also commencing a comprehensive study to test its technology on extending the preservation periods for donor organs. Preservation technology has the potential to prolong the shelf life of blood platelets and other collected biological materials. This medical breakthrough could greatly increase the global availability of precious living biological materials needed to save human lives and hundreds of millions of dollars each year in medical costs.
HyperBaric believes there are a number of benchmarks that investors should watch for during 2002-2003:
-- Announcement of pre-clinical trials for human infusion testing to
begin at one of America's leading blood laboratories during the
summer of 2002.
-- Initiation of FDA testing. The Company believes this could happen
as early as the end of 2002, or by early 2003.
-- FDA approval for beginning and successfully completing
pre-clinical trials.
-- One or more licensing agreements by 2003. HyperBaric intends to
enter into several licensing agreements with one or more major
companies that sell products to blood centers and hospitals.
National Capital Securities, Inc. (NCS) is a member of the National Association of Securities Dealers, CRD number 37702. In purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that NCS/DCI was recently compensated by HyperBaric for $5,000 due diligence fee and $2,500 per month for services provided payable in cash and 22,000 shares in 144 restricted stock. There may be a negotiable fee for any additional services rendered by NCS for HyperBaric. Further information about HyperBaric may be obtained at www.freeedgar.com.